Skip to main content
Premium Trial:

Request an Annual Quote

Biogen Renews, Expands Deal for Lexicon Technology

NEW YORK, Oct. 24-Biogen has renewed and expanded its license for Lexicon Genetics' knockout-based gene targeting technology, Lexicon said today.

 

The agreement expands upon a deal first struck in September 2000, whereby Biogen secured the rights to use Lexicon's "positive negative selection technology," a method to generate knockout mice useful in validating drug targets.

 

This license also gives Biogen non-exclusive rights to Lexicon's isogenic DNA gene targeting technology.

 

Financial details of this agreement were not revealed.

 

For further details, see the press release.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.